Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus LIQUID E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus LIQUID E Z PAQUE.
IOPAMIDOL-200 IN PLASTIC CONTAINER vs LIQUID E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent